John Wennerström

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics. Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

Akiram Therapeutics is a Swedish biotech company committed to developing innovative and targeted molecular radiotherapy for patients with incurable cancer. Our product combines a radiation component with a proprietary antibody to deliver radioactivity directly to cancer cells while minimizing damage to surrounding healthy tissues. Our research is based on cutting-edge discoveries made at Uppsala University, and our team is composed of experts in radiation sciences, cancer precision medicine, and drug development. At Akiram, our mission is to make targeted molecular radiotherapy widely accessible to cancer patients. We recognize that each patients cancer is unique and requires a personalized approach to treatment. By utilizing state-of-the-art radiopharmaceuticals and precision medicine, we aim to create more effective and personalized treatments for people fighting cancer.

NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden.  Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy.

SAGA Diagnostics is a personalised cancer medicine and disease monitoring company focused on molecular genetic analyses of circulating tumor DNA and tissue biopsies.

Bredbandsval.se är en oberoende jämförelsetjänst för bredband och TV. På www.bredbandsval.se kan du enkelt hitta och jämföra leverantörer och tjänster som erbjuds på din adress. Målet är att du som användare av tjänsten i lugn och ro ska kunna beställa den bästa tjänsten och spara tid och pengar. Allt du behöver veta är vilken adress du vill ha tjänsten på!

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.

Oxceed hjälper dig att spara tid i den finansiella rapporteringen, minskar risken för fel och ger dig värdefulla insikter om företagets ekonomi. Oxceed används av över 10 000 företag och 200 redovisningsbyråer i Sverige.

Vi är SaaS-bolaget som har utvecklat ett digitalt affärssystem som revolutionerar parkeringsförvaltningen för fastighetsägare och kommuner. Systemet automatiserar administrationen, ökar driftnettot och gör det möjligt att tjänstefiera parkeringsytor med exempelvis delad mobilitet och integrerad elbilsladdning. På Mobility46 vill vi hjälpa fastighetsägare, fastighetsförvaltare, parkeringsoperatörer och kommuner att äga och effektivisera sin parkeringsaffär, och för att göra detta behöver man få koll på sina parkeringstillgångar och anpassa erbjudandet efter sina parkeringskunders behov. Med ett digitalt affärssystem för parkeringsförvaltning ingår t.ex: 🚙 Automatiserad köhantering och tillsättning 🔑 Digitala nycklar ✔ Digitala avtal med Bank-ID 📊 Statistik och rapporter via digitala dashboards 💲 Automatiserad fakturahantering ⚡ Integrerad elbilsladdning & mobilitet 📱 Digital slutkundsupplevelse Detta minskar administrationen, ökar driftnettot och skapar nöjdare kunder. Välkommen att besöka vår hemsida eller höra av dig till oss om du vill veta mer.

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. Website: www.ossdsign.com Newsroom: https://news.cision.com/ossdsign-ab (Always consult Instructions for Use which accompany the products for complete indications, contraindications, warnings and precautions.)

Digitalizing Science to Improve Surgical Recovery Encare is a global leader in the implementation and continuous monitoring of ERAS® (Enhanced Recovery After Surgery) Protocols. Our mission is to transform scientific evidence into practical solutions that improve surgical outcomes, reduce variation in care, and optimize hospital performance. In partnership with the ERAS® Society, Encare provides: • The ERAS® Interactive Audit System (EIAS) — a digital platform for structured compliance tracking and continuous quality improvement. • The ERAS® Implementation Program (EIP) — a training program including a methodology for multidisciplinary change management and successful protocol adoption. ERAS® is a globally recognized standard of care that has been shown to: - Free up critical hospital resources and reduce overall costs - Reduce complications by up to 50% - Shorten hospital stays - Lower readmission rates - Improve staff satisfaction and long-term recovery Encare supports hospitals and healthcare systems in over 30 countries, helping them implement ERAS® Protocols with structure, consistency, and measurable results. With a proven track record of success, our solutions have contributed to significantly improved surgical outcomes and more efficient perioperative care across the globe. 🔗 Learn more: www.encare.net

Qthena. The only co-pilot with a purpose-built digital cockpit. Dive into the future with us here at ipQuants. Whether youre a legal professional or anyone battling with document-heavy tasks, Qthena promises clarity, convenience, and unparalleled efficiency. Transform your workflow, no matter its nature, with ipQuants. While Qthena shines brightest in the intricate alleys of legal processes, its adaptability knows no bounds. From legal analytics spanning EPO, USPTO, and German patent prosecution to any document-centric workflow, Qthenas intuitive design ensures the right insights surface precisely when needed. Experience the familiarity of spreadsheets, enhanced with our unique digital interface, providing project views and panels that redefine document collaboration. Join our mission: Leading digital transformation for all, one streamlined process at a time.

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics. Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

Společnost CHEIRÓN a.s., působí na trhu již od roku 1994. Hlavními aktivitami společnosti jsou vývoj, výroba, distribuce, import, export a servis zdravotnických prostředků. Během svého dlouholetého působení na trhu jsme se etablovali jako významný dodavatel zdravotnických prostředků v oboru anestezie a intenzivní péče. Jsme členem Asociace výrobců a dodavatelů zdravotnických prostředků. Vyvíjíme a vyrábíme spolehlivé elektrické odsávací přístroje se zvláštním důrazem na bezpečnost pacienta a obsluhy. Naše výrobky exportujeme do více než 60 zemí světa. Zákazníkům CHEIRÓN a.s. v České republice, kterými jsou poskytovatelé zdravotních služeb, dodáváme zdravotnické prostředky světových značek a poskytujeme odborné služby. Jsme spolehlivým, stabilním partnerem a reagujeme na měnící se požadavky a potřeby našich zákazníků. Významnou součástí společnosti je servisní, měřicí a kalibrační centrum, kde se provádí záruční a pozáruční servis veškerých vyráběných a distribuovaných zdravotnických prostředků, měření a kalibrace odpařovačů kapalných anestetik, defibrilátorů, monitorů vitálních funkcí, infuzních pump a lineárních dávkovačů. Servisní technici absolvují pravidelná odborná školení u výrobců distribuovaných zdravotnických prostředků.

The company was founded in 1984 under the name Biazet Ltd, the only Polish factory producing medical monitoring equipment. Manufactured in Bialystok, 8000 System monitors, have earned a well-deserved reputation in the country. By 1995, installed more than 7,000 in Polish hospitals. The company operated on the Polish market under several names, including: S&W Mediko Teknik, S&W Vickers, Artema, Axmeditec, Biameditek (till April 2024). Currently, the company is the exclusive distributor in Polish market the world-class medical equipment: Mindray(PMLS), Ambu, Sebia, Aerogen, Axlab, Milestone and others. Since 2010 CIRRO belongs to Indutrade Group, established in Sweden.

SenzaGen aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® test platform, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy.

Akiram Therapeutics is a Swedish biotech company committed to developing innovative and targeted molecular radiotherapy for patients with incurable cancer. Our product combines a radiation component with a proprietary antibody to deliver radioactivity directly to cancer cells while minimizing damage to surrounding healthy tissues. Our research is based on cutting-edge discoveries made at Uppsala University, and our team is composed of experts in radiation sciences, cancer precision medicine, and drug development. At Akiram, our mission is to make targeted molecular radiotherapy widely accessible to cancer patients. We recognize that each patients cancer is unique and requires a personalized approach to treatment. By utilizing state-of-the-art radiopharmaceuticals and precision medicine, we aim to create more effective and personalized treatments for people fighting cancer.